Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost–Utility Analysis

Overview of attention for article published in Drug Safety, June 2016

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 21,843 followers.

RT @HIV_Insight: Active Surveillance vs Spontaneous Reporting for 1st-Line ARV Medicines in #Namibia [a] https://t.co/cMSQ2c4rAi HT @UW_Pha…

Active Surveillance vs Spontaneous Reporting for 1st-Line ARV Medicines in #Namibia [a] https://t.co/cMSQ2c4rAi HT @UW_Pharmacy

RT @HIV_Insight: Active Surveillance vs Spontaneous Reporting for 1st-Line ARV Medicines in #Namibia [a] https://t.co/cMSQ2c4rAi HT @UW_Pha…

RT @HIV_Insight: Active Surveillance vs Spontaneous Reporting for 1st-Line ARV Medicines in #Namibia [a] https://t.co/cMSQ2c4rAi HT @UW_Pha…

RT @HIV_Insight: Active Surveillance vs Spontaneous Reporting for 1st-Line ARV Medicines in #Namibia [a] https://t.co/cMSQ2c4rAi HT @UW_Pha…

Active Surveillance vs Spontaneous Reporting for 1st-Line ARV Medicines in #Namibia [a] https://t.co/cMSQ2c4rAi HT @UW_Pharmacy